



9/22/04

1647/4#
JW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Avi J. ASHKENAZI, et al.

Application Serial No.: 10/020,445

Filed: October 24, 2001

For: **SECRETED AND
TRANSMEMBRANE
POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME**

) Examiner: Seharaseyon, Jegatheesan

) Art Unit: 1647

) Confirmation No.: 9983

) Attorney's Docket No.: 39780-2630 P1C74

) Customer No. 35489

EXPRESS MAIL LABEL NO. EL 977 678 291 US
DATE MAILED: SEPTEMBER 20, 2004

AMENDMENT AND RESPONSE TO OFFICE ACTION

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

In response to the Office Action mailed on April 20, 2004, in connection with the above-identified patent application, please enter the following amendments, and consider the following arguments. This response is timely filed requesting a Petition for Extension of Time for two months with necessary fees.

Enclosed herewith are pages 1-49 of U.S. Provisional Application No. 60/083,392, filed on April 29, 1998, and pages 1, 275 and 276 of PCT publication, WO 99/46281, corresponding to PCT application, PCT/US99/05028, filed on March 8, 1999, in support of Applicants' priority claim.

Also filed herewith is an Information Disclosure Statement providing sufficient identifying information regarding the BLAST results. Applicants respectfully request that the information listed in the Information Disclosure Statement be considered by the Examiner and be made of record in the above-identified application.

The present Amendment and Response is accompanied by the submission of declaration signed by all of the inventors, the consideration of which is respectfully requested. In addition,

enclosed herewith is the Amendment Under 37 C.F.R. §1.48(b) to correct the inventorship in the present application, the consideration of which is respectfully requested.

Amendments to the Specification begin on page 3 of this paper.

Amendments to the Claims are reflected in the listing of claims that begins on page 10 of this paper.

Remarks/Arguments begin on page 13 of this paper.